The industry is increasingly aware of the importance of corporate social responsibility (CSR) programmes – and Alex Kalomparis, Gilead’s vice president of public affairs for EMEA, says they ...

Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) – Stock analysts at Zacks Research reduced their Q3 2026 earnings per share estimates for shares of Gilead Sciences in a research report ...

Gilead Sciences has a twelve month low of $62.07 and a twelve month high of $114.77. Gilead Sciences (NASDAQ:GILD – Get Free Report) last issued its quarterly earnings data on Tuesday, February ...

Gilead Sciences has shored up its antibody-drug conjugate pipeline by licensing a candidate from German biotech Tubulis in a deal worth up to $415 million. The agreement includes an upfront ...

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

BARCELONA, Spain, March 3, 2025 /PRNewswire/ -- TCL CSOT, a global leader in display technology for over 15 years, has presented its APEX brand of premium display technology at MWC 2025, leading ...

Under the licensing agreement, Cadila Healthcare will receive a complete technology transfer of the Gilead manufacturing process to enabling production to be scaled up as quickly as possible.

A Bitcoin enthusiast poses for pictures during the kick-off of the Plan B Forum El Salvador, in San Salvador, El Salvador, January 30, 2025. REUTERS/Jose Cabezas/File Photo Bitcoin, the world's ...